Literature DB >> 20524212

Type I hyperprolinemia: genotype/phenotype correlations.

Audrey Guilmatre1, Solenn Legallic, Gary Steel, Alecia Willis, Gabriella Di Rosa, Alice Goldenberg, Valérie Drouin-Garraud, Agnès Guet, Cyril Mignot, Vincent Des Portes, Vassili Valayannopoulos, Lionel Van Maldergem, Jodi D Hoffman, Claudia Izzi, Caroline Espil-Taris, Simona Orcesi, Luisa Bonafé, Eric Le Galloudec, Hélène Maurey, Christine Ioos, Alexandra Afenjar, Patricia Blanchet, Bernard Echenne, Agathe Roubertie, Thierry Frebourg, David Valle, Dominique Campion.   

Abstract

Type I hyperprolinemia (HPI) is an autosomal recessive disorder associated with cognitive and psychiatric troubles, caused by alterations of the Proline Dehydrogenase gene (PRODH) at 22q11. HPI results from PRODH deletion and/or missense mutations reducing proline oxidase (POX) activity. The goals of this study were first to measure in controls the frequency of PRODH variations described in HPI patients, second to assess the functional effect of PRODH mutations on POX activity, and finally to establish genotype/enzymatic activity correlations in a new series of HPI patients. Eight of 14 variants occurred at polymorphic frequency in 114 controls. POX activity was determined for six novel mutations and two haplotypes. The c.1331G>A, p.G444D allele has a drastic effect, whereas the c.23C>T, p.P8L allele and the c.[56C>A; 172G>A], p.[Q19P; A58T] haplotype result in a moderate decrease in activity. Among the 19 HPI patients, 10 had a predicted residual activity <50%. Eight out of nine subjects with a predicted residual activity > or = 50% bore at least one c.824C>A, p.T275N allele, which has no detrimental effect on activity but whose frequency in controls is only 3%. Our results suggest that PRODH mutations lead to a decreased POX activity or affect other biological parameters causing hyperprolinemia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20524212     DOI: 10.1002/humu.21296

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  9 in total

1.  Genome-wide association study of NMDA receptor coagonists in human cerebrospinal fluid and plasma.

Authors:  J J Luykx; S C Bakker; W F Visser; N Verhoeven-Duif; J E Buizer-Voskamp; J M den Heijer; M P M Boks; J H Sul; E Eskin; A P Ori; R M Cantor; J Vorstman; E Strengman; J DeYoung; T H Kappen; E Pariama; E P A van Dongen; P Borgdorff; P Bruins; T J de Koning; R S Kahn; R A Ophoff
Journal:  Mol Psychiatry       Date:  2015-02-10       Impact factor: 15.992

2.  Long-term clinical outcome, therapy and mild mitochondrial dysfunction in hyperprolinemia.

Authors:  Steffi van de Ven; Thatjana Gardeitchik; Dorus Kouwenberg; Leo Kluijtmans; Ron Wevers; Eva Morava
Journal:  J Inherit Metab Dis       Date:  2013-10-31       Impact factor: 4.982

3.  Deletion size analysis of 1680 22q11.2DS subjects identifies a new recombination hotspot on chromosome 22q11.2.

Authors:  Tingwei Guo; Alexander Diacou; Hiroko Nomaru; Donna M McDonald-McGinn; Matthew Hestand; Wolfram Demaerel; Liangtian Zhang; Yingjie Zhao; Francisco Ujueta; Jidong Shan; Cristina Montagna; Deyou Zheng; Terrence B Crowley; Leila Kushan-Wells; Carrie E Bearden; Wendy R Kates; Doron Gothelf; Maude Schneider; Stephan Eliez; Jeroen Breckpot; Ann Swillen; Jacob Vorstman; Elaine Zackai; Felipe Benavides Gonzalez; Gabriela M Repetto; Beverly S Emanuel; Anne S Bassett; Joris R Vermeesch; Christian R Marshall; Bernice E Morrow
Journal:  Hum Mol Genet       Date:  2018-04-01       Impact factor: 6.150

4.  Evidence for association of hyperprolinemia with schizophrenia and a measure of clinical outcome.

Authors:  Catherine L Clelland; Laura L Read; Amanda N Baraldi; Corinne P Bart; Carrie A Pappas; Laura J Panek; Robert H Nadrich; James D Clelland
Journal:  Schizophr Res       Date:  2011-06-08       Impact factor: 4.939

5.  Physical exercise reverses cognitive impairment in rats subjected to experimental hyperprolinemia.

Authors:  Andréa G K Ferreira; Emilene B Scherer; Maira J da Cunha; Fernanda R Machado; Aline A da Cunha; Jeferson S Graeff; Carlos A Netto; Angela T S Wyse
Journal:  Neurochem Res       Date:  2011-07-27       Impact factor: 3.996

Review 6.  Reciprocal Control of Thyroid Binding and the Pipecolate Pathway in the Brain.

Authors:  André Hallen; Arthur J L Cooper
Journal:  Neurochem Res       Date:  2016-08-12       Impact factor: 3.996

7.  Hyperprolinemia type I caused by homozygous p.T466M mutation in PRODH.

Authors:  Rina Hama; Jun Kido; Keishin Sugawara; Toshiro Nakamura; Kimitoshi Nakamura
Journal:  Hum Genome Var       Date:  2021-07-20

8.  Biochemical and clinical features of hereditary hyperprolinemia.

Authors:  Hiroshi Mitsubuchi; Kimitoshi Nakamura; Shirou Matsumoto; Fumio Endo
Journal:  Pediatr Int       Date:  2014-08       Impact factor: 1.524

9.  The structural origin of metabolic quantitative diversity.

Authors:  Seizo Koshiba; Ikuko Motoike; Kaname Kojima; Takanori Hasegawa; Matsuyuki Shirota; Tomo Saito; Daisuke Saigusa; Inaho Danjoh; Fumiki Katsuoka; Soichi Ogishima; Yosuke Kawai; Yumi Yamaguchi-Kabata; Miyuki Sakurai; Sachiko Hirano; Junichi Nakata; Hozumi Motohashi; Atsushi Hozawa; Shinichi Kuriyama; Naoko Minegishi; Masao Nagasaki; Takako Takai-Igarashi; Nobuo Fuse; Hideyasu Kiyomoto; Junichi Sugawara; Yoichi Suzuki; Shigeo Kure; Nobuo Yaegashi; Osamu Tanabe; Kengo Kinoshita; Jun Yasuda; Masayuki Yamamoto
Journal:  Sci Rep       Date:  2016-08-16       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.